Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis

The third-generation aromatase inhibitors (AIs: anastrozole, letrozole, and exemestane) have now become standard adjuvant endocrine treatment for postmenopausal estrogen receptor-positive breast cancer complementing chemotherapy and surgery. Because of the absence of direct head-to-head comparisons...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xihe, Liu, Lei, Li, Kai, Li, Wusheng, Zhao, Li, Zou, Huawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599049/
https://www.ncbi.nlm.nih.gov/pubmed/26491345
http://dx.doi.org/10.2147/OTT.S88179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599049/
https://www.ncbi.nlm.nih.gov/pubmed/26491345
http://dx.doi.org/10.2147/OTT.S88179

Ejemplares similares